Conduction System Pacing Reduces Hospitalization and Improves Ejection Fraction

Optimizing Ventricular Synchrony in Systolic Heart Failure

Heart failure affects more than 64 million people globally, with symptomatic patients facing a one-year mortality rate exceeding 20 percent [1, 2]. In patients with left ventricular systolic dysfunction, electrical dyssynchrony (a delay in the coordinated contraction of the heart chambers) often leads to accelerated myocardial failure and a worsened prognosis [3, 4]. Although optimal medical therapy remains the standard of care, many patients remain symptomatic with a reduced left ventricular ejection fraction, necessitating interventions like cardiac resynchronization therapy to restore mechanical efficiency [5, 6]. Large-scale clinical evidence has established that cardiac resynchronization therapy reduces the risk of death from any cause (relative risk 0.73; 95 percent confidence interval, 0.62 to 0.85) in this population [4, 6]. A recent analysis evaluates whether emerging pacing techniques, such as left bundle-branch pacing (a method of stimulating the heart's natural conduction system to achieve more physiological activation), can further refine clinical outcomes for patients who do not respond to traditional biventricular pacing [7].

The Clinical Burden of Electrical Dyssynchrony

Heart failure remains a global health priority, affecting more than 64 million individuals worldwide. For clinicians managing this population, the prognosis remains guarded, particularly following an acute decompensation. Data indicate that acute heart failure is associated with 1-year mortality rates of 23.6% in North America and Europe, a statistic that underscores the necessity of identifying and treating reversible contributors to ventricular dysfunction. One such contributor is electrical dyssynchrony, a condition where the heart's electrical signals fail to coordinate ventricular contractions effectively, leading to mechanical inefficiency and the progression of heart failure. In clinical practice, electrical dyssynchrony most commonly presents as left bundle-branch block, a conduction delay that disrupts the synchronous activation of the left ventricle. This specific conduction system disease is highly prevalent among patients with systolic dysfunction, affecting 20% to 30% of patients with reduced left ventricular ejection fraction. When the left ventricle fails to contract in a coordinated fashion, the resulting dyssynchrony further reduces cardiac output and accelerates myocardial remodeling. The researchers note that identifying these patients early is vital, as delayed referral for device therapy in this population is associated with significantly worse clinical outcomes. Because conduction system disease is a primary driver of heart failure progression in patients with left ventricular systolic dysfunction, timely resynchronization is essential to stabilize or improve cardiac function. Recognizing that nearly one-third of patients with a reduced ejection fraction may harbor a left bundle-branch block allows clinicians to prioritize those who may benefit from advanced pacing strategies before irreversible ventricular remodeling occurs.

Mortality Benefits of Biventricular Pacing

Biventricular pacing, a standard approach to cardiac resynchronization therapy, utilizes a specific lead configuration to address the mechanical consequences of electrical dyssynchrony. In this procedure, clinicians use two leads to stimulate the right ventricle and left ventricle simultaneously, a configuration designed to restore the coordinated contraction pattern lost in patients with conduction system disease. By bypassing delayed electrical pathways, this approach aims to optimize ventricular filling and stroke volume in patients who remain symptomatic despite receiving optimal medical therapy. The clinical efficacy of this intervention is supported by robust longitudinal data. An individual patient-level meta-analysis encompassing 5 randomized clinical trials with a total of 3872 patients demonstrated that biventricular pacing significantly reduces the risk of death. Over a median follow-up period of 23.7 months, the researchers found that biventricular pacing was associated with lower all-cause mortality compared with medical therapy or an implantable cardioverter-defibrillator. Specifically, the mortality rate was 13.7% in the biventricular pacing group versus 20.8% in the control group, representing a hazard ratio of 0.66 (95% CI, 0.57-0.77). For practicing physicians, these findings provide a clear evidence base for utilizing resynchronization therapy to extend survival in patients with advanced heart failure and reduced ejection fraction.

Physiological Advantages of Conduction System Pacing

Cardiac resynchronization therapy encompasses two primary modalities: biventricular pacing and conduction system pacing. While biventricular pacing relies on simultaneous stimulation of both ventricles, conduction system pacing uses a single lead to stimulate the His bundle or left bundle branch, directly engaging the heart's intrinsic electrical pathways. This more physiological approach aims to replicate natural ventricular activation more closely than traditional methods. Data from a meta-analysis of 7 small randomized clinical trials, which included 408 patients with heart failure and a left ventricular ejection fraction of 40% or less, suggest that this direct stimulation may offer superior functional recovery. In this analysis, conduction system pacing was associated with a mean difference of 2.06% improvement in left ventricular ejection fraction compared with biventricular pacing (P = .03). Beyond improvements in systolic function, the use of conduction system pacing appears to translate into tangible reductions in healthcare utilization for patients with advanced heart failure. An observational study involving 1778 patients with a left ventricular ejection fraction of 35% or less who were undergoing cardiac resynchronization therapy compared the two pacing strategies. The researchers found that conduction system pacing was associated with significantly lower rates of heart failure hospitalization at 12% compared to 19% for those receiving biventricular pacing. This represents a hazard ratio of 0.67 (95% CI, 0.52-0.86), indicating that direct stimulation of the conduction system may provide a more durable clinical stabilization for patients with severe left ventricular dysfunction.

Mitigating Pacing-Induced Cardiomyopathy

Clinicians should also consider resynchronization for patients requiring chronic ventricular pacing, which is typically indicated for the management of symptomatic bradycardia. While traditional right ventricular pacing is a standard treatment for atrioventricular block (a condition where electrical impulses are delayed or blocked between the atria and the ventricles), the procedure is not without long-term physiological costs. Right ventricular pacing may result in ventricular dyssynchrony, an uncoordinated contraction of the ventricular walls that can lead to an increased risk of left ventricular systolic dysfunction, or a reduction in the heart's ability to pump blood effectively. The clinical benefit of avoiding traditional right ventricular leads was demonstrated in a trial of 249 patients without heart failure who were undergoing permanent pacing for bradycardia related to atrioventricular block. The researchers compared the incidence of pacing-induced cardiomyopathy, defined as a decrease in left ventricular ejection fraction of at least 10% to a total of less than 50%. The study reported that conduction system pacing was associated with significantly lower rates of pacing-induced cardiomyopathy at 6% compared to 15% in the right ventricular pacing group (P = .01). These findings suggest that by maintaining a more physiological activation pattern, conduction system pacing may protect against the iatrogenic cardiac deterioration often associated with chronic right ventricular stimulation.

Clinical Indications and Therapeutic Goals

Current clinical guidelines establish clear parameters for the utilization of cardiac resynchronization therapy in the management of heart failure. Cardiac resynchronization therapy is recommended for patients with symptomatic heart failure despite optimal medical therapy, a left ventricular ejection fraction of 35% or less, and left bundle-branch block. This specific subset of patients, who continue to experience symptoms such as dyspnea or fatigue even with maximized pharmacological treatment, represents a high-risk group where electrical dyssynchrony significantly contributes to disease progression. By targeting those with a reduced left ventricular ejection fraction (the percentage of blood pumped out of the left ventricle with each contraction) and a left bundle-branch block (a delay or blockage of electrical impulses along the left side of the heart), clinicians can address the underlying mechanical inefficiency that characterizes advanced systolic dysfunction. The primary objective of this intervention is the correction of uncoordinated cardiac contractions. Cardiac resynchronization therapy restores synchronous ventricular activation in patients with heart failure, reduced left ventricular ejection fraction, and left bundle-branch block, or in those requiring chronic ventricular pacing. By coordinating the timing of the ventricles, the therapy addresses the mechanical delays that often lead to further cardiac remodeling. Beyond the immediate physiological correction, the long-term clinical benefits are substantial. The researchers note that cardiac resynchronization therapy may improve left ventricular function, decrease heart failure hospitalizations, and reduce mortality. These outcomes underscore the importance of timely referral for device therapy, as the restoration of synchronous contraction directly translates to improved patient survival and a reduction in the burden of acute care episodes in daily practice.

References

1. Vaduganathan M, Docherty KF, Claggett B, et al. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. The Lancet. 2022. doi:10.1016/s0140-6736(22)01429-5

2. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021. doi:10.1093/eurheartj/ehab368

3. Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. European Heart Journal. 2013. doi:10.1093/eurheartj/eht290

4. Cleland JG, Daubert J, Erdmann E, et al. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. New England Journal of Medicine. 2005. doi:10.1056/nejmoa050496

5. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure. New England Journal of Medicine. 2004. doi:10.1056/nejmoa032423

6. Wells GA, Parkash R, Healey JS, et al. Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. Canadian Medical Association Journal. 2011. doi:10.1503/cmaj.101685

7. Cheng Y, Wang Z, Li Y, Qi J, Liu J. Left bundle branch pacing in heart failure patients with left bundle branch block: A systematic review and meta-analysis.. Pacing and clinical electrophysiology : PACE. 2022. doi:10.1111/pace.14405